Skip to main content
HCAT
NASDAQ Technology

Health Catalyst Announces 9% Workforce Reduction and CPO Departure Amid Strategic Restructuring

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.31
Mkt Cap
$101.549M
52W Low
$0.955
52W High
$5.062
52W Position info
37% above low
Off High info
74% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

HCAT sits 37% above its 52-week low of $0.955.

Summary

Health Catalyst is implementing a 9% workforce reduction and eliminating the Chief People Officer role as part of a strategic initiative to cut costs and streamline operations, following a period of significant financial losses.


Key Events · Corporate Governance and Compliance · HCAT

  • Workforce Reduction Authorized

    The Board authorized a global workforce reduction of approximately 9% and the elimination of 100 open positions as part of "Project Nexus" to transform the operating model and reduce costs.

  • Chief People Officer Role Eliminated

    Linda Llewelyn will cease to serve as Chief People Officer effective June 1, 2026, due to the elimination of her role in connection with the workforce reduction. She will transition to a senior advisor role.

  • Strategic Cost-Cutting Initiative

    This initiative aims for a meaningful reduction in the company's cost structure, following a recent 10-K report detailing a widened net loss and declining cash.


Analysis · HCAT · Technology

This 8-K details significant operational changes at Health Catalyst, directly addressing the financial challenges highlighted in its recent 10-K, which reported a widened net loss and declining cash. The company's Board authorized a 9% global workforce reduction and the elimination of 100 open positions as part of "Project Nexus," a strategic initiative to transform its operating model and reduce costs. This aggressive cost-cutting measure is a critical step for the company to improve its financial health and extend its operational runway. The departure of the Chief People Officer is a direct consequence of this restructuring, with the role being eliminated. Investors should monitor the upcoming 10-Q for further details on the financial impact of these changes.

At the time of this filing, HCAT was trading at $1.31 on NASDAQ in the Technology sector, with a market capitalization of approximately $101.5M. The 52-week trading range was $0.96 to $5.06. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HCAT - Latest Insights

HCAT
Jul 17, 2026, 6:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.20
Real-time Price: $2.08 info
Change: -$0.120 (-5%) info
Market Cap: $153.7M info
HCAT
Jun 22, 2026, 3:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $1.69
Real-time Price: $2.08 info
Change: +$0.395 (+23%) info
Market Cap: $153.7M info
HCAT
Jun 08, 2026, 7:12 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $2.08 info
Change: +$0.3558 (+21%) info
Market Cap: $153.7M info
HCAT
Jun 04, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.56
Real-time Price: $2.08 info
Change: +$0.525 (+34%) info
Market Cap: $153.7M info
HCAT
Jun 04, 2026, 9:03 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $2.08 info
Change: +$0.530 (+34%) info
Market Cap: $153.7M info